{
  "context": {
    "rules": [
      "Rule1: If the manufacturing process for Drug Candidate A is approved, then mass production of Drug Candidate A does not begin.",
      "Rule2: If the patent for Substance Z is approved, then a patent for Substance Z is filed.",
      "Rule3: Either Drug Candidate A is released to the market or the manufacturing process for Drug Candidate A is not approved.",
      "Rule4: If Competitor Drug X is launched, then Drug Candidate A is not released to the market.",
      "Rule5: Either Competitor Drug X is launched or a generic version of Drug Candidate A becomes available.",
      "Rule6: If clinical trials for Drug Candidate A are initiated, then clinical trials for Drug Candidate A are completed.",
      "Rule7: Either clinical trials for Drug Candidate A are initiated or, if a grant for Substance Z is not awarded, then Project X receives research funding.",
      "Rule8: If sales of Drug Candidate A decline, then the price of Drug Candidate A is reduced.",
      "Rule9: Either sales of Drug Candidate A decline or Drug Candidate A loses market share.",
      "Rule10: If Drug Candidate A loses market share, then, should a generic version of Drug Candidate A become available, Drug Candidate A is not released to the market.",
      "Rule11: If research focus shifts to Disease Y, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed.",
      "Rule12: If a new indication for Drug Candidate A is studied, then either human trials for Drug Candidate B are initiated or an alternative formulation for Drug Candidate B is developed.",
      "Rule13: If a breakthrough finding for Disease Y occurs, then research focus shifts to Disease Y.",
      "Rule14: Either a breakthrough finding for Disease Y occurs or Drug Candidate A is repurposed for an existing condition.",
      "Rule15: Either a partnership with Company B is formed or, if Drug Candidate A is repurposed for an existing condition, then a new indication for Drug Candidate A is studied.",
      "Rule16: Either a licensing agreement with Company B is signed or a partnership with Company B is not formed.",
      "Rule17: If clinical trials for Drug Candidate A are completed, then side effects for Drug Candidate A are observed.",
      "Rule18: If clinical trials for Drug Candidate A are completed, then regulatory approval for Drug Candidate A is not granted.",
      "Rule19: If research on Substance Z is published, then, if Substance Z is discovered, a grant for Substance Z is awarded.",
      "Rule20: If a conference presentation on Substance Z is made, then, if Substance Z is discovered, a grant for Substance Z is awarded.",
      "Rule21: If peer review for Substance Z is completed, then either research on Substance Z is published or a conference presentation on Substance Z is made.",
      "Rule22: If the patent for Substance Z is challenged, then a legal dispute over Substance Z is initiated.",
      "Rule23: If the patent for Substance Z is challenged, then a legal dispute over Substance Z is not initiated.",
      "Rule24: If side effects for Drug Candidate A are observed, then regulatory approval for Drug Candidate A is granted.",
      "Rule25: If the preclinical stage for Drug Candidate B is initiated, then animal testing for Drug Candidate B is completed.",
      "Rule26: Either the preclinical stage for Drug Candidate B is initiated or a grant for Substance Z is awarded.",
      "Rule27: If human trials for Drug Candidate B are initiated, then animal testing for Drug Candidate B is not completed.",
      "Rule28: If an alternative formulation for Drug Candidate B is developed, then animal testing for Drug Candidate B is not completed.",
      "Rule29: If it is not the case that the manufacturing process for Drug Candidate A being approved leads to mass production of Drug Candidate A beginning, then the manufacturing process for Drug Candidate A is revised.",
      "Rule30: If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then the patent for Substance Z is approved.",
      "Rule31: If it is not the case that Substance Z being discovered leads to a grant for Substance Z being awarded, then a patent for Substance Z is not filed.",
      "Rule32: If it is not the case that clinical trials for Drug Candidate A being completed leads to regulatory approval for Drug Candidate A being granted, then clinical trials for Drug Candidate A are suspended.",
      "Rule33: If neither human trials for Drug Candidate B are initiated nor an alternative formulation for Drug Candidate B is developed, then the manufacturing process for Drug Candidate A is approved.",
      "Rule34: If it is not the case that the failure of clinical trials for Drug Candidate A being completed to lead to regulatory approval for Drug Candidate A being granted results in clinical trials for Drug Candidate A not being suspended, then an investigation into Drug Candidate A is launched.",
      "Rule35: If peer review for Substance Z is not completed, then the patent for Substance Z is challenged."
    ],
    "facts": [
      "Fact1: Substance Z is discovered.",
      "Fact2: Project X does not receive research funding.",
      "Fact3: The manufacturing process for Drug Candidate A is not revised.",
      "Fact4: An investigation into Drug Candidate A is not launched.",
      "Fact5: The price of Drug Candidate A is not reduced.",
      "Fact6: A licensing agreement with Company B is not signed."
    ]
  },
  "question": "A grant for Substance Z is awarded."
}